Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders' Equity

v3.24.1.1.u2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Ordinary Shares
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2022 $ 27,999 $ 126 $ 451,150 $ (422,927) $ (350)
Beginning balance (in shares) at Dec. 31, 2022   12,598,641      
Issuance of ordinary shares, net 235 $ 2 233    
Issuance of ordinary shares, net (in shares)   207,192      
Share-based compensation expense 393   393    
Net loss (9,889)     (9,889)  
Unrealized income (loss) on available-for-sale securities 219       219
Ending balance at Mar. 31, 2023 18,957 $ 128 451,776 (432,816) (131)
Ending balance (in shares) at Mar. 31, 2023   12,805,833      
Beginning balance at Dec. 31, 2022 27,999 $ 126 451,150 (422,927) (350)
Beginning balance (in shares) at Dec. 31, 2022   12,598,641      
Net loss (38,371)        
Ending balance at Dec. 31, 2023 (6,403) $ 135 454,759 (461,298) 1
Ending balance (in shares) at Dec. 31, 2023   13,499,003      
Issuance of ordinary shares, net 7,217 $ 30 7,187    
Issuance of ordinary shares, net (in shares)   2,971,411      
Share-based compensation expense 138   138    
Net loss (7,101)     (7,101)  
Unrealized income (loss) on available-for-sale securities (1)       $ (1)
Ending balance at Mar. 31, 2024 $ (6,150) $ 165 $ 462,084 $ (468,399)  
Ending balance (in shares) at Mar. 31, 2024   16,470,414